Skip to content
Home » Craif selected as a finalist in the world’s largest medical technology accelerator’s “Medtech Innovator 2024 Cohort”

Craif selected as a finalist in the world’s largest medical technology accelerator’s “Medtech Innovator 2024 Cohort”

Craif Co., Ltd.
Craif selected as a finalist in the world’s largest medical technology accelerator’s “Medtech Innovator 2024 Cohort”
……
Craif Co., Ltd. (location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter “Craif”), which provides the “My Signal Series” that leads to the early detection and prevention of cancer, is a partner of the world’s largest medical technology accelerator, the U.S. “Medtech We are pleased to announce that we were the only Japanese company selected as one of the 65 finalists chosen from approximately 1,300 companies from around the world for the Innovator 2024 Cohort.
[Image: https://prtimes.jp/i/41883/168/resize/d41883-168-4b3c428de70e7e43b57d-0.png&s3=41883-168-50549eaa6855e1fe0c7127f76e8f03b6-1444×156.png ]
This accelerator program selects startups with innovative medical technology from around the world and receives support from leading corporate partners and industry experts in the medical industry for approximately four months. Of the approximately 600 companies selected so far, 310 medical devices have received US regulatory approval and are in use in clinical practice. Craif will continue to take on the challenge of achieving our company’s mission of “creating a society where people can live out their natural lives” by widely
disseminating new initiatives for early detection and prevention of cancer.
[List of Medtech Innovator 2024 Cohort finalists]
https://medtechinnovator.org/65-startups-named-to-medtech-innovator-2024-cohort/ ■What is MedTech Innovator?
MedTech Innovator is the world’s largest medical technology
accelerator that supports startup companies in the medical device, diagnostic, and digital health fields. Its mission is to improve people’s health by accelerating the growth of healthcare-transforming companies. Approximately 600 companies have completed the program to date, and 310 of them have received US regulatory approval and are marketing their products. This year, more than 1,300 companies applied and 65 startups were selected.
■ About Craif
Craif is a venture company founded in 2018 from Nagoya University. We have the basic technology “NANO IP(R)︎ (NANO Intelligence Platform)” that detects disease-related biological substances such as microRNA with high accuracy from easily collected body fluids such as urine. Craif is working on the development of tests using NANO IP(R)︎ to realize early detection of cancer and medical care tailored to each individual.
■ About “My Signal(R)︎ Series”
“MySignal(R)︎ Series” is a cancer risk test that leads to early detection and prevention. This series includes “MySignal Scan,” which uses microRNA x AI to evaluate cancer risk with high precision in the early detection field, “MySignal Light,” which more easily evaluates cancer risk, and cancer prevention, which uses microRNA x AI to evaluate cancer risk with high precision. It consists of “MySignal Navi,” a genetic test specialized in. All tests can be performed without putting any strain on the body, simply by collecting urine or saliva. First, learn about your genetic predisposition to cancers and suggest preventive actions tailored to your individual risk. Furthermore, through regular examinations, we will be able to detect cancers that require immediate attention. That is the comprehensive cancer prevention of the “MySignal(R) Series”. The seven cancer types supported by MySignal Scan and MySignal Navi are pancreatic cancer, colon cancer, stomach cancer, esophageal cancer, lung cancer, breast cancer, and ovarian cancer. Please see the website
(https://misignal.jp/) for details.
【Company Profile】
Company name: Craif Inc. (pronunciation: Craif, English notation: Craif Inc.) Representative: Representative Director Ryuichi Onose
Established: May 2018
Capital: 100 million yen (as of March 1, 2024)
Business: Research and development of next-generation tests aimed at early detection of diseases mainly in the cancer field and realization of personalized medicine, next-generation cancer risk test “MySignal Scan”, easy cancer risk test ” Provision of “MySignal Light” and “MySignal Navi,” a genetic test specialized for cancer.
Head Office: ITP Hongo Office 5F, 2-25-7 Yushima, Bunkyo-ku, Tokyo URL: https://craif.com/
More details about this release:
https://prtimes.jp/main/html/rd/p/000000168.000041883.html



%d